Premium
α‐Interferon in myelofibrosis: a case report
Author(s) -
Dalla K. P.,
Zeigler Z. R.,
Shadduck R. K.
Publication year - 1994
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1994.tb04802.x
Subject(s) - myelofibrosis , medicine , hepatosplenomegaly , bone marrow , asymptomatic , fibrosis , haematopoiesis , extramedullary hematopoiesis , interferon , bone marrow suppression , myeloid , metaplasia , pathology , pancytopenia , gastroenterology , immunology , chemotherapy , stem cell , biology , disease , genetics
Summary. A patient with advanced myeloid metaplasia was treated with α‐interferon (29 months) with a remarkable response. He had anaemia, thrombocytopenia and hepatosplenomegaly with infarction. The initial bone marrow showed replacement with fibrosis with no evident haemopoietic cells. Post‐therapy, the patient became asymptomatic, transfusion independent and had normal blood counts. The repeat bone marrow was 30% cellular with 1 + reticulin and no fibrosis. Treatment was well tolerated without appreciable side‐effects. These results indicate that prolonged therapy with α‐interferon can improve haemopoiesis and reverse marrow fibrosis.